http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109021057-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0061 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00 |
| filingDate | 2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109021057-B |
| titleOfInvention | Farnesoid X receptor agonist |
| abstract | The invention relates to a farnesoid X receptor agonist. The invention discloses a compound shown as the following formula: the compound OBN-K has the agonistic effect on FXR and EC 50 The value is comparable to obeticholic acid. OBN-K can obviously reduce the serum ALP and TBIL levels of a cholestatic cirrhosis model rat caused by bile duct ligation, obviously improve the hepatic fibrosis score, and has the effect of treating PBC equivalent to that of obeticholic acid. OBN-K can also obviously reduce serum ALT and AST levels of rats induced by MCD to NASH model, obviously improve the grading of liver pathological NASH, and has the effect of treating NASH equivalent to that of obeticholic acid. The incidence rate of adverse reactions of pruritus caused by OBN-K is obviously lower than that of obeticholic acid. |
| priorityDate | 2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 217.